阿托伐他汀对急性冠脉综合征患者外周血炎性因子的影响

被引:7
作者
唐皓
梁艳冰
翟诚顺
马中富
机构
[1] 广州市中山大学附属第一医院普内科
基金
广东省科技计划;
关键词
冠状动脉疾病; 阿托伐他汀; 炎性因子;
D O I
暂无
中图分类号
R541 [心脏疾病];
学科分类号
1002 ; 100201 ;
摘要
目的探讨急性冠脉综合征(ACS)患者外周血单个核细胞环氧化酶2(COX-2)、血小板活化因子乙酰水解酶(PAF-AH)与血清超敏C反应蛋白(hsCRP)水平的变化及阿托伐他汀对它们的影响与意义。方法测定健康对照组(40例)、ACS组(45例)治疗前后外周血单个核细胞的COX-2、PAF-AH及hsCRP水平,并作比较。结果健康对照组COX-2[(33.8±4.6)ng/ml]、PAF-AH[(30.2±1.5)μmol·min-1·L-1]、hsCRP[(1.1±0.8)g/L],与ACS组治疗前COX-2[(50.4±5.8)ng/ml]、PAF-AH[(18.7±3.1)μmol·min-1·L-1]、hsCRP[(19.3+5.6)g/L]差异有统计学意义(P<0.05),ACS组治疗后COX-2[(38.1±3.2)ng/ml]、PAF-AH[(28.0±2.1)μmol·min-1·L-1]、hsCRP[(7.4±1.8)g/L]与治疗前差异有统计学意义(P<0.05)。结论炎性因子COX-2、PAF-AH、hsCRP与ACS的发病明显相关,阿托伐他汀可降低ACS患者的COX-2、hsCRP,升高PAF-AH,对减轻炎症反应、稳定斑块起着重要作用。
引用
收藏
相关论文
共 6 条
[1]  
Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Pearson TA,Mensah GA,Alexander RW,et al. Circulation . 2003
[2]  
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. Blankenberg S,Stengel D,Rupprecht HJ,et al. Journal of Lipid Research . 2003
[3]  
Common polymorphisms of cyclooxygenase-2and prostaglandin E2receptor and increased risk for acute coronary syndrome in coronary artery disease. Szczeklik W,Sanak M,Rostoff P,et al. Thrombosis and Haemostasis . 2008
[4]  
Platelet-activating factor acetylhydrolases in health and disease. Tjoelker LW,Stafforini DM. Biochimica et Biophysica Acta . 2000
[5]  
Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fi- broblasts: implications for lung inflammation and cancer. Martey CA,Pollock SJ,Turner SJ,O’Reilly KM,Baglole CJ,Phipgs RP,Sime PJ. American Journal of Physiology Lung Cellular and Molecular Physiology . 2004
[6]  
Cyclooxygenase-2 and atherosclerosis. Linton M F,Fazio S. Current Opinion in Lipidology . 2002